Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QMF149 Twisthaler · 1 trial · 1 indication
Defined as the number of days from start of treatment up to the first date when an asthma exacerbation becomes serious. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.
| Arm | Type | Description |
|---|---|---|
| QMF149 Twisthaler® 500/400 | EXPERIMENTAL | QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD) |
| Mometasone Twisthaler® | ACTIVE_COMPARATOR | Mometasone Twisthaler®, 400 µg QD |
| Name | Type | Description |
|---|---|---|
| QMF149 Twisthaler® | DRUG | Once daily via multi-dose dry-powder inhaler |
| Mometasone Twisthaler® | DRUG | Once daily via multi-dose dry-powder inhaler |
Inclusion Criteria: * Patients with a documented diagnosis of persistent asthma and who were currently treated with or qualified for treatment with both ICS and long-acting beta2-agonist (LABA) combination * Patients demonstrating an increase in forced expiration volume in 1 second (FEV1) of ≥ 12% ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
QMF149 Twisthaler is an investigational small molecule therapy developed by Novartis AG for the treatment of asthma. It is delivered as an inhaled combination product through the Twisthaler device and was studied in adolescent and adult patients with asthma. It remains in Phase 2 clinical development.
QMF149 Twisthaler is being developed for the treatment of asthma in adolescent and adult patients aged 12 years and older. Its clinical program focused on respiratory care, and the drug has been studied in a Phase 2 trial evaluating safety in this patient population.
QMF149 Twisthaler is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis is the sponsor of the clinical program evaluating this inhaled asthma therapy.
QMF149 Twisthaler is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. One Phase 2 trial has been completed, and no active trials are currently listed for this asset.
QMF149 Twisthaler was evaluated in the completed Phase 2 trial NCT00941798, titled Safety of QMF149 Twisthaler in Adolescent and Adult Patients With Asthma. The trial enrolled 2,283 patients across the United States, Brazil, Colombia, Czechia, Hungary, India, Peru, Slovakia, and South Korea.
Yes, QMF149 Twisthaler and QMF149 Twisthaler® refer to the same investigational asthma therapy from Novartis AG. The registered trademark symbol appears in the product name and in the title of its Phase 2 trial, but both names describe the identical drug candidate.